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Abstract
Background: Delivery of tobramycin by inhalation to the lungs of patients with cystic fibrosis (CF)
who are infected with Pseudomonas aeruginosa has been proven to be effective and safe. The aerosol
administration allows high concentrations of tobramycin to be delivered to the site of infection with
limited systemic absorption. In rare patients, systemic absorption of inhaled tobramycin may be
significant enough to produce toxic effects, such as renal and vestibular toxicities.
Case presentation: We report a patient with CF who developed recurrent eosinophilia and
severe persistent bronchospasm following repeated administration of preservative-free tobramycin
by inhalation, beginning at 16 months of age. Also, he developed similar signs and symptoms when
he was administered tobramycin intravenously on one occasion at 5 1/2 years. The patient had a
history of environmental allergies. Temporal sequence of his signs and symptoms after each
administration of tobramycin (similar to re-challenge testing), and his improvement after
discontinuation of the drug strongly suggest an adverse drug reaction.
Conclusion: Hypersensitivity reaction should be considered in patients who develop recurrent
eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation
or by intravenous administration.
Background
The delivery of tobramycin by inhalation to the lungs of
patients with cystic fibrosis (CF) who are infected with
Pseudomonas aeruginosa has been proven to be effective
and safe [1]. The aerosol administration allows high con-
centrations of tobramycin to be delivered to the site of
infection with limited systemic absorption. The portion of
inhaled tobramycin available for systemic absorption
includes approximately 10% of the total dose that is deliv-
ered to the lungs, and some that gets to the oropharynx
and eventually swallowed [1].
There is poor systemic absorption of aerosolized tobramy-
cin into the lungs among patients with CF, and its absorp-
tion from alveolar space into the pulmonary circulation is
rate-limited [2]. Several studies have consistently docu-
mented low serum concentrations of tobramycin follow-
ing its aerosolized administration [1]. Rarely, renal [3]
and vestibular toxicities [4] have been described following
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inhaled tobramycin. A single case report describes devel-
opment of a rash following inhaled tobramycin, in a
patient who had developed a similar rash following a
course of intravenous gentamicin and piperacillin-tazo-
bactam [5]. These examples illustrate that systemic
absorption of inhaled tobramycin may be significant
enough to produce toxic effects among patients with CF.
Inhaled tobramycin has been associated with cough and
alteration of voice [6,7]. Development of acute bronchos-
pasm has been associated with use of intravenous prepa-
rations of tobramycin for aerosol administration. This
effect is thought to be related to antioxidants and preserv-
atives contained within these preparations [1]. Thus,
bronchospasm is less likely to occur with use of TOBI®
[6,7], the preservative free tobramycin solution for inhala-
tion (TSI) that has been licensed by the United States
Food and Drug Administration.
Eosinophilia has been reported to be associated with
intravenous administration of tobramycin, including a
patient treated for Gram-negative bacteremia [8], and
among nine of 88 patients who received tobramycin in
combination with cefamandole for peritonitis [9]. Fur-
thermore, a patient with end-stage renal disease who was
treated for sepsis with parenteral tobramycin and vanco-
mycin developed persistent fever, eosinophilia and rash.
Although temporal sequence had suggested vancomycin
as the probable cause [10], the possible contribution of
tobramycin could not be totally excluded.
We report a patient with CF who developed recurrent eosi-
nophilia and severe persistent bronchospasm following
repeated administration of TOBI®.
Case Presentation
The patient was diagnosed as having CF, based on prena-
tal testing that was performed because he had a brother
with CF. His CF transmembrane conductance regulator
(CFTR) protein genetic analysis showed homozygosity for
the  ΔF508 mutation. At a year of age, his treatments
included pancreatic enzymes for his pancreatic insuffi-
ciency; a multivitamin; nebulized albuterol and cromolyn
sodium in the treatment of occasional coughing and
wheezing that were thought to be attributable to hyperre-
active airways; and daily dornase alfa, which has been
used routinely as preventive therapy in infants at our
Cystic Fibrosis Center since 1996.
At 16 months of age, the patient presented with wheezing,
and was found to harbor Pseudomonas aeruginosa in his
deep throat culture for the first time. He was prescribed a
one-month course of preservative-free TSI, 150 mg/2.5
mL twice daily by nebulization. With this therapy, his
cough and wheezing improved, only to worsen when the
TSI was discontinued. Therefore, he was started on every
other month administration of TSI that appeared to be
recurrently associated with improvement in his respira-
tory status, even though Pseudomonas was not again docu-
mented in his throat cultures at that time. A year later his
TSI dose was increased to 300 mg/5 mL twice daily.
At 2 years of age, as part of a routine screen, the patient
was noted to have an elevated serum IgE level of 843 IU/
mL (normal range, 2–35 IU/mL), and his eosinophil
count (11%) was increased several fold (Table 1). The
possibility of allergic bronchopulmonary aspergillosis
was considered. However, anti-Aspergillus  antibodies (<
1:8 by complement fixation) as well as skin scratch testing
for Aspergillus were negative. As the patient's eosinophilia
persisted (15–20%), further investigations over the subse-
quent three years included a re-check of Aspergillus anti-
body titers (including A. fumigatus, A. flavus, and A. niger),
stool sample for ova and parasites (including wet mount,
permanent stain and modified acid fast stain), Giardia
antigen in stool, and Toxocara canis antibody levels; all
were negative. His radioallergosorbent test (RAST) for
common allergens in the northeastern part of the United
States showed low level response to Alternaria alternata
(77%) and to D. farinae (71%). A chest radiograph was
clear.
The patient continued to suffer from recurrent wheezing
and therefore was prescribed nebulized budesonide, oral
montelukast, and infrequent 3–5 day bursts of oral pred-
nisolone. When the patient was nearly 5 years old he
began performing pulmonary function testing (PFT) on a
routine basis, and demonstrated normal lung function,
without improvement following bronchodilator adminis-
Table 1: Summary of TSI administration, pulmonary status, and hematologic profiles before 5 years
Before TSI Therapy TSI started 150 mg/2.5 
mL twice daily
On TSI 150 mg/2.5 mL 
twice daily
TSI Increased to 300 mg/
5 mL twice daily
On TSI 300 mg/5 mL 
twice daily
Age 6 months 16 months 2 years 2 1/2 years 4 years
Pulmonary Status No wheezing (+) wheezing; 1st (+) throat 
culture for P. aeruginosa
(+) wheezing (+) wheezing (+) wheezing
WBC (/mm3) 15.2 NA 9.1 12 11.2
Eosinophils (%) 1N A 1 1 1 5 2 0
IgE (IU/mL) NA NA 843 NA 299
Abbreviations: TSI, tobramycin solution for inhalation; WBC, white blood cell count; NA, not availableBMC Pediatrics 2007, 7:11 http://www.biomedcentral.com/1471-2431/7/11
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tration, during a month while he was off TSI (Table 2). As
he had not been found to harbor Pseudomonas for more
than three years, it was decided to stop his every other
month TSI.
At 5 1/2 years the patient developed purulent nasal drain-
age, coughing and wheezing. At that time, his deep throat
culture revealed Staphylococcus aureus and Serratia marces-
cens. As he did not respond to therapy with oral amoxicil-
lin/clavulanate, ciprofloxacin, azithromycin, and
prednisone, he was hospitalized and treated with intrave-
nous ceftazidime and tobramycin. His symptoms
improved over the first few days of the hospitalization,
but then he developed increased wheezing and dyspnea.
His pulmonary function testing revealed a severe obstruc-
tive pattern, which improved with bronchodilator admin-
istration (from a forced expiratory volume in 1 second of
27% to 34% of predicted based on his height and age). He
also had eosinophilia (13%) documented while he was
receiving the intravenous antibiotics. A chest radiograph
revealed a slight right middle lobe infiltrate. He was
treated with a two week course of oral prednisone, with
rapid improvement in his symptoms. His pulmonary
function improved within a week and his eosinophils nor-
malized about a week off intravenous tobramycin. His
chest radiograph then revealed clear lung fields.
In further work-up of the patient's recurrent eosinophilia,
the possibility of a fungal sinus infection was proposed by
an Infectious Disease consultant. Therefore, the patient
underwent computed tomography studies of his sinuses
that revealed bilateral opacification of the maxillary
sinuses. A sinus biopsy was consistent with chronic sinusi-
tis. The sinus specimen cultures revealed Alcaligenes xylos-
oxidans, but were negative for fungus and acid fast
organisms. Because of the apparent worsening of his
chronic clinical condition half a year after discontinuation
of every other month TSI therapy, and given the presence
of the Gram-negative organisms Serratia and Alcaligenes in
his airways, the patient was restarted on every other
month TSI.
He developed recurrent wheezing once his prednisone
was discontinued. He was subsequently started on every
other day prednisone, at a dose of 0.8 mg/kg/day, which
helped control his wheezing. At 6 years TSI was discontin-
ued as he was found to harbor Alcaligenes xylosoxidans in
his deep throat culture, which was resistant to tobramy-
cin.
He did well until 6 1/2 years when he developed an upper
respiratory infection with associated sinusitis and cough-
ing. A throat culture demonstrated Pseudomonas aeruginosa
for the first time since his early childhood for which he
was prescribed oral ciprofloxacin and TSI. Within several
days, he developed severe wheezing with an associated
severe obstructive pattern on pulmonary function testing
with eosinophilia (14%). At that time, review of his med-
ical record revealed a strong relationship between use of
tobramycin and the patient's eosinophilia and bronchos-
pasm (Tables 1 and 2). This prompted permanent discon-
tinuation of the patient's TSI.
Over the subsequent 12 months, the patient did not dem-
onstrate eosinophilia. He tolerated weaning off chronic
prednisone by the age of 7 years. He continued to have
elevated serum IgE levels, however was noted to be trend-
ing down while off TSI (Table 2). He has had recurrent
mild bronchospasm, although he has not had further epi-
sodes of severe airway obstruction.
Discussion
Tobramycin associated recurrent eosinophilia with severe
persistent bronchospasm has not been reported previ-
ously. The temporal sequence of the patient's signs and
symptoms, after every administration of TSI or tobramy-
cin intravenously, strongly suggest an adverse drug reac-
tion (ADR).
An ADR is a noxious and unintended response to a drug
at therapeutic doses [11] – in our patient, documented as
eosinophilia and severe obstructive airway disease after
every administration of tobramycin. The Naranjo scale
confirms tobramycin as the highly probable cause of his
ADR. This is a reliable (inter-raters [r = 0.92] and intra-
Table 2: Summary of TSI administration, pulmonary function, and hematologic profiles at 5 years and after
Off TSI Intravenous 
tobramycin ~1 week
~1 weeks post 
intravenous tobramycin
Off TSI On TSI 300 mg/5 mL twice 
daily
Off TSI Off TSI
Age 5 years 5 1/2 years 5 1/2 years 6 years 6 1/2 years 7 years 7 1/2 years
Pulmonary Function FVC 105%
FEV1 90%
FVC 45%
FEV1 27%
FVC 76%
FEV1 64%
FVC 103%
FEV1 93%
FVC 49 %
FEV1 32 %
FVC 90%
FEV1 81%
FVC 91%
FEV1 78%
WBC (/mm3) 7.9 16 15.8 NA 17.7 13.5 9.9
Eosinophils (%) 21 3 1 N A 1 4 0 1
IgE (IU/mL) 123 165 NA NA 205 306 166
Abbreviations: TSI, tobramycin solution for inhalation; WBC, white blood cell count; FVC, forced vital capacity; FEV1, forced expiratory volume in 
1 second; NA, not availableBMC Pediatrics 2007, 7:11 http://www.biomedcentral.com/1471-2431/7/11
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raters [r = 0.91] reliability, p < 0.001) and valid (with con-
sensual, content and concurrent validity) probability scale
consisting of a simple questionnaire used to assess ADR
[12]. Although his serum IgE remained elevated, there was
no recurrence of eosinophilia after discontinuation of the
TSI. He has had episodes of bronchospasm; however, not
as severe as when he was receiving TSI. Furthermore, other
emergent causes of his signs and symptoms (such as aller-
gic bronchopulmonary aspergillosis and parasitemia)
have been excluded.
Hypersensitivity reaction to tobramycin is a plausible
explanation in our patient. This has been reported in an
adult patient with CF who developed urticaria, pruritis,
and difficulty of breathing after the third dose of intrave-
nous tobramycin [13]. In our patient, hypersensitivity
reaction is supported by his history of environmental
allergies.
The patient might have benefited from a diagnostic bron-
choscopy when he developed unexplained respiratory
symptoms with associated eosinophilia. This procedure
might have documented eosinophilia, Pseudomonas, fun-
gus, or another infectious organism in the bronchoalveo-
lar lavage fluid, and such findings could have guided his
therapy.
There are in vitro data to suggest that aminoglycoside accu-
mulation in non-CF cells is under regulation by effectors
and inhibitors of the CF transmembrane conductance
(CFTR) channel. This regulation is lost among CF cells
with ΔF508 mutations with inhibition of exocytosis since
the CFTR channel is inoperable. This results in accumula-
tion of aminoglycoside within the affected cells [14]. As
patients exposed to higher drug concentrations are more
at risk for ADR, it is possible that our patient had signifi-
cant tissue accumulation of tobramycin leading to his
symptoms.
Any drug has the potential to produce an ADR. Medical
personnel taking care of children with complicated medi-
cal conditions such as CF, need to maintain a high index
of suspicion in differentiating complications of the pri-
mary illness from an unexpected consequence of pre-
scribed medications [15].
Conclusion
Hypersensitivity reaction should be considered in patients
who develop recurrent eosinophilia and deterioration of
pulmonary function following the use of tobramycin by
inhalation or by intravenous administration.
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